Supplement Material

Time (hr)	% of parent remaining after serum incubation		
	Human	Rat	Monkey
0	100.0%	100.0%	100.0%
2	99.6%	99.4%	99.7%
8	96.0%	96.4%	100.0%
24	98.8%	89.0%	99.6%
48	97.9%	87.8%	99.9%
72	99.2%	86.5%	99.5%

Table I (Supplemental file). **Percentage of ARC15105 remaining in nuclease rich serum of different species.**

	Patients with AMI	Controls	P
Subgroups n (%)			
Acute myocardial infarction	21 (100)		
ST-elevation myocardial infarction	8 (38)		
non ST-elevation myocardial infarction	13 (62)		
Volunteers		21 (100)	
Young		9 (43)	
age-matched		12 (57)	
Male sex n (%)	17 (81)	10 (48)	0.024
Medical history n (%)			
Diabetes mellitus	5 (24)	0 (0)	0.017
Hypertension	16 (76)	3 (14)	<0.001
Hyperlipidemia	10 (48)	1 (5)	0.002
previous AMI	5 (24)	0 (0)	0.017
current smoker	6 (29)	1 (5)	0.038
Medical therapy at the time of blood sampling n (%)			
angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB)	17 (81)	0 (0)	<0.001
Aspirin	21 (100)	0 (0)	<0.001
Clopidogrel	21 (100)	0 (0)	<0.001
β-Blockers	15 (71)	0 (0)	<0.001
Heparins	21 (100)	0 (0)	<0.001
Calcium channel blockers (CCB)	3 (14)	0 (0)	0.072
Proton pump inhibitors	14 (67)	0 (0)	<0.001
Statins	16 (76)	0 (0)	<0.001
Anti-diabetics	2 (10)	0 (0)	0.147
Percutaneous coronary intervention (PCI) prior to blood drawing n (%)	16 (76)	NA	NA
Age: median (IQR)	65 (57-80)	45 (26-61)	0.123
Body mass index (BMI), kg/m²: median (IQR)	26 (23-30)	23 (22-26)	0.217
Mean arterial pressure (MAP; mmHg): median (IQR)	102 (806-105)	100 (92-103)	0.206
platelet count x 10³/uL: median (IQR)	176 (154-205)	172 (162-227)	0.537
haemoglobin g/dl: median (IQR)	8.0 (7.0-10.6)	5.4 (4.1-6.0)	0.758
leukocyte count x 10³/uL: median (IQR)	12.6 (11.5-13.3)	13.0 (12.5-13.5)	<0.001

Table II (Supplemental file). Demographics of study participants. IQR=interquartile range; NA=not applicable.

Figure I (Supplemental file). Inhibition of von Willebrand Factor (VWF) in three cynomolgus monkeys after SC injection of 20mg/kg ARC15105.